Massimo Framarini

Dr. Massimo Framarini


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in International Archives of Medicine
Verified
Journal Article
Open access
PDF file
SPSara Piciucchi
Sara Piciucchi
CMCarlo Milandri
Carlo Milandri
GVGiorgio M Verdecchia
Giorgio M Verdecchia
MFMassimo Framarini
Massimo Framarini
EAElena Amadori
Elena Amadori
GGGiampaolo Gavelli
Giampaolo Gavelli
We describe a case of acute hiatal hernia during chemotherapy, in a female patient previously treated with gastrectomy.

22 November 2023 in Surgeries
Verified
Journal Article
Open access
PDF file
MFMassimo Framarini
Massimo Framarini
FDFabrizio D'Acapito
Fabrizio D'Acapito
DPDaniela Di Pietrantonio
Daniela Di Pietrantonio
FTfrancesca tauceri
francesca tauceri
PLPaolo Di Lorenzo
Paolo Di Lorenzo
Giorgio ErcolaniGiorgio Ercolani
Giorgio Ercolani
Epithelial ovarian cancer (EOC) is the most frequent cause of death among women with gynecologic malignant tumors. Primary debulking surgery (PDS) with maximal surgical effort to reach completeness of cytoreduction, followed by chemotherapy, has become the standard of care; moreover, some experiences have shown that a comprehensive treatment approach of surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) could improve the prognosis of ovarian cancer. We carried out a retrospective analysis of all consecutive sixty-six patients diagnosed with primary advanced or recurrent ovarian cancer who underwent debulking surgery plus HIPEC in a single center between September 2005 and October 2020. For 33 patients with primary EOC, with a median follow-up period of 70 months, the median overall survival was 56 months (range: 48.1–96.9); and the median disease-free survival (DFS) was 13 months (range: 19.9–53.7). In the recurrent population, the median follow-up period was 78 months, the median overall survival (OS) was 82 months (range: 48.1–96.9), and the median DFS was 17 months (range: 19.7–53.0). In our study, we have found that CRS plus HIPEC is feasible, with very low rates of major complications and good results in terms of overall survival.

15 June 2024 in Surgeries
Verified
Journal Article
Open access
PDF file
MFMassimo Framarini
Massimo Framarini
FDFabrizio D'Acapito
Fabrizio D'Acapito
DPDaniela Di Pietrantonio
Daniela Di Pietrantonio
FTfrancesca tauceri
francesca tauceri
GVGiovanni Vittimberga
Giovanni Vittimberga
Giorgio ErcolaniGiorgio Ercolani
Giorgio Ercolani
Gastric cancer (GC) is the fifth most diagnosed cancer, but it is the third leading cause of cancer death worldwide. Despite the likelihood of gastric cancer metastasizing to the peritoneum, optimal management strategies for this population remain undefined. We carried out a retrospective analysis to present our findings on patients with advanced gastric cancer (AGC) with peritoneal metastases (CP) who underwent neoadjuvant chemotherapy followed by gastrectomy + hyperthermic intraperitoneal chemotherapy (HIPEC). To better understand the data, we compared these patients with AGC patients without CP who were treated with neoadjuvant chemotherapy and surgery, as well as with another group of patients who underwent upfront surgery. Patients who undergo surgery and HIPEC achieve a higher survival rate than patients in the literature who undergo only palliative chemotherapy with a median overall survival of 28 months with a low incidence of major complications.